アキューメン・ファーマシューティカルズ
Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.33 | $0 | -$24M |
| 2025 Q4 | -0.42 | $0 | -$19M |
| 2025 Q3 | -0.44 | $0 | -$30M |
| 2025 Q2 | -0.68 | $0 | -$32M |
| 2025 Q1 | -0.48 | $0 | -$34M |
| 2024 Q4 | -0.62 | $0 | -$27M |
| 2024 Q3 |
| -0.50 |
| $0 |
| -$25M |
| 2024 Q2 | -0.34 | $0 | -$17M |